Publications by authors named "Anzhi Li"
RET (Rearranged during transfection) kinase is a validated target for non-small cell lung cancer (NSCLC). In 2020, two selective RET inhibitors, selpercatinib and pralsetinib were approved by the US FDA. However, high treatment costs and clinically acquired resistance (e.
View Article and Find Full Text PDFArticle Synopsis
- * A bibliometric analysis of research from 2009 to 2023 identified 106 relevant articles, revealing that China, the United States, and Japan lead in publications, while the Second Military Medical University is the most influential institution in this field.
- * Key findings show a growing trend in research, with frequent keywords like hydrogen, oxidative stress, inflammation, and apoptosis; future studies are expected to focus on hydrogen's role in early brain injury, ischemia-reperfusion injury, and hypothermia treatment.
Background: Intracranial aneurysm (IA) is a cerebrovascular disease with a high mortality rate due to ruptured subarachnoid hemorrhage. While Krüppel-like factor 6 (KLF6) dysregulation has been implicated in cancer and cardiovascular diseases, its role in IA remains unclear.
Materials And Methods: The GSE122897 and GSE15629 datasets were downloaded from the Gene Expression Omnibus database.
EGFR degraders in non-small-cell lung cancer: Breakthrough and unresolved issue.
Chem Biol Drug Des
April 2024
The epidermal growth factor receptor (EGFR) has been well validated as a therapeutic target for anticancer drug discovery. Osimertinib has become the first globally accessible third-generation EGFR inhibitor, representing one of the most advanced developments in non-small-cell lung cancer (NSCLC) therapy. However, a tertiary Cys797 to Ser797 (C797S) point mutation has hampered osimertinib treatment in patients with advanced EGFR-mutated NSCLC.
View Article and Find Full Text PDF